Certara Inc is a leading provider of software and services that streamline the drug development process, helping biopharmaceutical companies bring new therapies to market more efficiently. The company specializes in optimizing preclinical and clinical development through advanced modeling and simulation, as well as utilizing innovative technologies to enhance decision-making in drug discovery and development. By leveraging their proprietary software platforms and extensive expertise, Certara supports clients in process optimization, regulatory compliance, and data analysis, ultimately contributing to improved patient outcomes and accelerated access to new medications. Read More
RADNOR, Pa., Feb. 27, 2026 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced that Company management will participate in the following investor conferences:
RADNOR, Pa., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced that it will release financial results for the fourth quarter and full year of 2025 before market open on Thursday, February 26th, 2026. Company management will host a conference call to discuss financial results at 8:30AM ET.
The biosimulation market was sent into a tailspin in the closing months of 2025 as Certara (Nasdaq:CERT), a global leader in model-informed drug development, saw its market valuation crater by 23%. The precipitous drop followed a Q3 earnings report that, while beating on some bottom-line metrics, signaled a worrying
ArrowMark’s sharp reduction in its Alight stake comes at a moment when the market is questioning whether the company can turn its consulting-heavy work into steadier recurring revenue, and that tension may say more about sentiment than about the strength of the platform itself.
RADNOR, Pa., Oct. 31, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced that Company management will participate in the following investor conferences:
RADNOR, Pa., Oct. 10, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that it will release financial results for the third quarter of 2025 after the market close on Thursday, November 6th, 2025. Company management will host a conference call to discuss financial results at 5:00PM ET.
RADNOR, Pa., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced that Company management will participate in the following investor conferences:
